Martina Spotti

CHIP is a common, age-related condition where mutated blood stem cells expand without causing blood disorders. CHIP raises the risk of hematological malignancies, chronic inflammatory diseases (like heart & lung disease), & lung cancer. This manuscript shows that CHIP somatic clones in blood—especially TET2 mutant ones—migrate into tumors, reshape immunity, drive progression, and promote recurrence. The ability of a somatic clonal expansion in the hematopoietic compartment, to regulate malignant progression in another tissue represents a new perspective in cancer biology. #CHIP #LCMS #cancer #biology #AACR25 nejm.org/doi/full/10.10…

One of the most important trials presented and published in 2023

Hospital Alemán-IGR. Rancontre Alumni Gustave Roussy. @ggabuin @FerMosele @Yules86 Martina Spotti @GustaveRoussy

Presenting efficacy and safety of pembrolizumab in TNBC in a real-world setting #ESMO23 with @MartinaSpotti @layalerached @CapuBaldini @SakkalMS @ElieRassy @BarbaraPistill2 @champiatMD @almasrihouss Next steps exploring blood based and imaging biomarkers! @GustaveRoussy

Dans les congrès il faut marcher Beaucoup Et aller voir les posters Souvent très intéressants Ici des données précieuses de toxicités de l’association chimio + immuno (Pembrolizumab) dans les cancers du sein en neoadjuvant Merci 🙏 @MartinaSpotti @layalerached et al de @GustaveRoussy Particulièrement intéressé personnellement par les toxicités cutanées … #ESMO2023

Today in #SIOG2022 presenting the results on CHIP in phase I patients @CapuBaldini @GustaveRoussy @SIOGorg

Happy to share with you this collaborative work. Thanks to all my colleagues! @CapuBaldini @Nathachaput @Matthieurd @RobertoFerrara_ @drcmassard @BenjaminBesseMD @MichotJM @champiatMD @VinGoldschmidt @DanlosF @ 👉👉 doi.org/10.1080/147371…

I truly enjoy meeting alumni when they return for reunions @Yale @YaleAlumni As a professor and college graduate (D’port ‘84), I shared our cancer program @YaleCancer @SmilowCancer, advances in immune therapy for cancer and my great experiences back in New Haven @YaleMedicine

Ayer en Universo BRAF. Charla TED interdisciplinaria en Oncología sobre distintos tipos de tumores con mutaciones BRAF. Gracias @MariaBluthgen por tu clara y excelente exposición. #oncology #pathology #lungcancer

@fedekava12 GRACIAS @fedekava12 💪🏻💪🏻💪🏻🏃🏽🏃🏽‍♀️ #running #CarreraMaya

Otros 10k y primeros 10k para @martina_spotti , gran carrera!! Felicitaciones y a seguir siempre un paso adelante!! #carreramaya #running #correr #entrenamiento #buenaonda #argentina #superacion instagram.com/p/Cd_jzDGvDFZ/…

@myESMO #colorectalcancer Preceptorship #LATAM @Betzabe100 @Juanma19712012 1st meeting in 2.5y - great to see and hug good friends! #accamargo

So pleased to meet new and old friends at #ESMO Latin America Summit 😊! Great gastric and esophageal cancer session with a sneak peak 👀at the new #esmoguidelines ! @myESMO @FlorianLordick

A Big Thanks @LizzySmyth1 and @FlorianLordick for sharing your knowledge and also support this ESMO SUMMIT LATAM! It was a great experience 😊

Today we finish our COLORECTAL CANCER PRECEPTORSHIP @myESMO in Mexico City! It has been an amazing experience. Thanks to all the participants, speakers @hastud2 @draivs @Juanma19712012 and my co-chairs Dirk Arnol, @RachelRiechelm2 @incanMX #colorectalcancer

Durva consol in unresect stg III NSCLC w driver mtns: - 43 pts: KRAS (26; 8 G12C), EGFR (8, 6 del19/ex21), BRAF (5, 4 V600E), ALK (4) - PD-L1+ in 85% - overall: mPFS 17.5; mOS 47m - mPFS NR KRASm G12C v 8.1m EGFRm 19/21 v 7.8m V600E/ALK p=0.02 @OncoAlert ejcancer.com/article/S0959-…

A special pts population that needs to be studied further. First study with so many mutated pts post CRT-durvalumab… thanks to all co-authors

Impressive results of the VISION study of Lu177-PSMA-617 in PSMA-positive mCRPC with significant PFS and OS benefit!! #ASCO21 @ASCO @ASCOPost @ASCO_pubs @OncoAlert @urotoday

5 years between POPLAR 2nd line trial to positive adjuvant study. ACCELERATION is really the key word in clinical research. (image from @APassaroMD ) #asco21

Excelentes resultados en iDFS y % de pacientes vivos a 3 años con el agregado de #durvalumab a la neoadyuvancia en #TNBC Taxano: nab-pacli. Sera aplicable en Argentina? #ASCO2021